Pharmacokinetic-pharmacodynamic relationships between pirarubicin exposure and hematotoxicity: Clinical application using only one blood sample

Anti-Cancer Drugs

Volumn 9, Issue 6, 1998, Pages 503-509

  Leca, François René ^a   Marchiset Leca, Dominique ^a   Galeani, Anne ^a   Noble, Alex ^a   Catalin, Jacques ^b  

^a Ctr Hosp Departemental C   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Anthracyclines; Hematotoxicity; Pharmacodynamics; Pharmacokinetics; Pirarubicin

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; MESNA; METHOTREXATE; NAVELBINE; PIRARUBICIN; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CORRELATION FUNCTION; DOSE RESPONSE; DRUG SCREENING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE; LEUKOPENIA; MALE; PRIORITY JOURNAL;

EID: 0031870248     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Agata N, Hirano SI, Hara Y, et al. A comparison of pirarubicin with other anthracyclines on the cardiovascular system. Pharmacometrics 1991; 41: 467-74.
2. Hirano S, Wakazono K, Agata N, Iguchi H, Tone H. Comparison of cardiotoxicity of pirarubicin, epirubicin and doxorubicin in the rat. Drugs Exp Clin Res 1994; XX: 153-60.
3. Herait P. THP-adriamycine: etat du développement clinique d'une nouvelle anthracycline en france. Path Biol 1990; 38: 64-8.
4. Sridhar KS, Samy TS, Koch G, et al. Phase 1 study of 4′-O-tetrahydropyranyladriamycin. Advances in Experimental and Clinical Chemotherapy. Workshop Pirarubicin (15th ICC), Istanbul/Turkey 1987.
5. Herait P, Poutignat N, Marty M, Bugat R. Early assessment of a new anticancer drug analogue - are the historical comparisons obsolete? The French experience with pirarubicin. Eur J Cancer 1992; 28A: 1670-6.
6. Marchiset-Leca D, Leca FR, Galeani A, Noble A, Iliadis A. A limited sampling strategy for the study of pirarubicin pharmacokinetics in human. Cancer Chemother Pharmacol 1995; 36: 233-8.
7. Robert J, David M, Huet S, Chauvergne J. Pharmacokinetics and metabolism of pirarubicin in advanced cancer patients. Eur J Cancer Clin Oncol 1988; 24: 1289-94.
8. Robert J, Monnier A, Poutignat N, Herait PA Pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients. Cancer Chemother Pharmacol 1991; 29: 75-9.
9. Marchiset-Leca D, Leca FR, Galeani A, Noble A, Catalin J. Pharmacokinetics and metabolism of pirarubicin in humans: correlation with pharmacodynamics. Cancer Chemother Pharmacol 1995; 36: 239-43.
10. Miller A, Schmidt CG. Clinical pharmacology and toxicity of 4′-O-tetrahydropyranyladriamycin. Cancer Res 1987; 47: 1461-5.
11. Nagasawa K, Yokoyama T, Ohnishi N, et al. Pharmacokinetics of pirarubicin in pediatric patients. J Pharmacobio-Dyn 1991; 14: 222-30.
12. Raber MN, Newman RA, Lu K, et al. Phase I clinical trial and pharmacokinetic evaluation of 4′-O-tetrahydropyranyladriamycin (THP-adriamycin). Cancer Chemother Pharmacol 1989; 23: 311-5.
13. Marchiset-Leca D, Leca F. Highly sensitive method for the determination of a new anthracycline: pirarubicin. Chromatographia 1993; 35: 435-8.
14. Ratain MJ, Schilsky RL, Conley BA, Egorin MJ. Pharmacodynamics in cancer therapy. J Clin Oncol 1990; 24: 1739-53.
15. Mader RM, Zilg H, Schlappack O, et al. Pharmacokinetics of 4′-O-tetrahydropyranyladriamycin given on a weekly schedule in patients with advanced breast cancer. Cancer Chemother Pharmacol 1995; 37: 91-6.
16. Robert J, Hoerni B. Age dependence of the early-phase pharmacokinetics of doxorubicin. Cancer Res 1983; 43: 4467-9.
17. Wade JR, Kelman AW, Kerr DJ, Robert J, Whiting B. Variability in the pharmacokinetics of epirubicin. Cancer Chemother Pharmacol 1992; 29: 391-5.